(GA ba pen tin)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Neurontin: 100 mg, 300 mg, 400 mg
Generic: 100 mg, 300 mg, 400 mg
Gralise Starter: 300 & 600 mg (78 ea) [contains soybean lecithin]
Neurontin: 250 mg/5 mL (470 mL) [strawberry anise flavor]
Generic: 250 mg/5 mL (5 mL, 6 mL, 470 mL, 473 mL)
Fanatrex FusePaq: 25 mg/mL (420 mL) [contains saccharin sodium, sodium benzoate]
Gralise: 300 mg [contains soybean lecithin]
Gralise: 600 mg
Neurontin: 600 mg, 800 mg [scored]
Generic: 600 mg, 800 mg
Brand Names: U.S.
- Fanatrex FusePaq
- Gralise Starter
- Anticonvulsant, Miscellaneous
- GABA Analog
Gabapentin is structurally related to GABA. However, it does not bind to GABAA or GABAB receptors, and it does not appear to influence synthesis or uptake of GABA. High affinity gabapentin binding sites have been located throughout the brain; these sites correspond to the presence of voltage-gated calcium channels specifically possessing the alpha-2-delta-1 subunit. This channel appears to be located presynaptically, and may modulate the release of excitatory neurotransmitters which participate in epileptogenesis and nociception.
Variable, from proximal small bowel by L-amino transport system; saturable process; dose-dependent
Vd: 58 ± 6 L; CSF concentrations are ~20% of plasma concentrations
Proportional to renal function; urine (as unchanged drug)
Clearance: Apparent oral clearance is directly proportional to CrCl: Clearance in infants is highly variable; oral clearance (per kg) in children <5 years of age is higher than in children ≥5 years of age
Time to Peak
Immediate release: Infants 1 month to Children 12 years: 2 to 3 hours; Adults: 2 to 4 hours; Gralise: 8 hours
Infants 1 month to Children 12 years: 4.7 hours
Adults, normal: 5 to 7 hours; increased half-life with decreased renal function; anuric adult patients: 132 hours; adults during hemodialysis: 3.8 hours
Special Populations: Renal Function Impairment
In CrCl less than 30 mL/minute, half-life is approximately 52 hours (immediate release). In moderate and severe renal impairment, Cl was decreased to 3 and 1 L/hour, respectively, compared with 5 to 7 L/hour in nonrenal impairment patients (ER).
The half-life in anuric patients is approximately 132 hours on nondialysis days; during dialysis, half-life is reduced to 3.8 hours (immediate release). Gabapentin is significantly removed by hemodialysis.
Special Populations: Children
Children between 1 mo and younger than 5 y achieved approximately 30% lower exposure (AUC) than that observed in those 5 y and older. Gabapentin elimination half-life averaged 4.7 h and was similar across the age groups studied. When normalized per body weight. The Cl was highly variable in infants younger than 1 y.
Use: Labeled Indications
Postherpetic neuralgia: Management of postherpetic neuralgia (PHN) in adults.
Seizures, partial onset (excluding Gralise): As adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and pediatric patients 3 years and older with epilepsy.
Epilepsy: Adjunctive therapy for the management of adult patients with epilepsy who are not satisfactorily controlled by conventional therapy.
Neuropathic pain, diabetic peripheral neuropathy, fibromyalgia, postoperative pain (adjunct), restless legs syndrome (RLS), hot flashes
Hypersensitivity to gabapentin or any component of the formulation
Postherpetic neuralgia: Oral:
Day 1: 300 mg, Day 2: 300 mg twice daily, Day 3: 300 mg 3 times daily; dose may be titrated as needed for pain relief (range: 1,800 to 3,600 mg/day in divided doses, daily doses >1,800 mg do not generally show greater benefit)
Gralise only: Day 1: 300 mg, Day 2: 600 mg, Days 3 to 6: 900 mg once daily, Days 7 to 10: 1,200 mg once daily, Days 11 to 14: 1,500 mg once daily, Days ≥15: 1,800 mg once daily
Seizures, partial onset: Oral (excluding Gralise):
Initial: 300 mg 3 times daily; increase dosage based on response and tolerability; usual dosage: 900 to 1,800 mg/day administered in 3 divided doses; doses of up to 2,400 mg/day have been tolerated in long-term clinical studies; up to 3,600 mg/day has been tolerated in short-term studies
Note: If gabapentin is discontinued or if another anticonvulsant is added to therapy, it should be done slowly over a minimum of 1 week.
Cough, chronic (refractory) (off-label use): Adults: Oral: Immediate release: 300 mg once daily on Day 1, followed by dosage escalation of an additional 300 mg per day until cough symptoms cease, side effects are intolerable, or a maximum tolerated dose of 1,800 mg/day in 2 divided doses is reached (ACCP [Gibson 2016]; Ryan 2012). Reassessment of risk-benefit profile should be done at 6 months before continuing treatment (ACCP [Gibson 2016]).
Diabetic neuropathy (off-label use): Oral: Immediate release: 900 to 3,600 mg/day (Bril 2011)
Hot flashes (off-label use): Oral: Immediate release: Day 1: 300 mg at bedtime, Day 2: 300 mg twice daily, followed by 300 mg 3 times/day for 4 weeks and then tapered off (Butt 2008)
Neuropathic pain (off-label use): Oral: Immediate release: 300 to 3,600 mg/day (Attal 2010; Dworkin 2010)
Neuropathic pain, critically ill patients (off-label use): Oral: Immediate release: Initial: 100 mg 3 times daily in combination with IV opioids; maintenance: 300 to 1,200 mg 3 times daily; maximum dose: 3,600 mg daily (Barr 2013)
Postoperative pain (adjunct; off-label use): Oral: Immediate release: 300 to 1,200 mg given the night before, 1 to 2 hours prior to surgery or immediately following surgery (Doleman 2015; Peng 2007; Yu 2013)
Restless legs syndrome (RLS) (off-label use): Oral: Immediate release: Initial: 300 mg once daily 2 hours before bedtime. Doses ≥600 mg/day have been given in 2 divided doses (late afternoon and 2 hours before bedtime). Dose may be titrated every 2 weeks until symptom relief achieved (range: 300 to 1,800 mg/day). Suggested maintenance dosing schedule: One-third of total daily dose given at 12 pm, remaining two-thirds total daily dose given at 8 pm. (Garcia-Borreguero 2002; Happe 2003; Saletu 2010; Vignatelli 2006)
Social anxiety disorder (off-label use): Oral: Initial: 300 mg twice daily; increase dose based on response and tolerability in increments of no more than 300 mg/day up to a maximum of 3,600 mg/day given in 3 divided doses. Doses for responders ranged from 900 to 3,600 mg/day in the clinical trial (Pande 1999). Additional data may be necessary to further define the role of gabapentin in this condition.
Refer to adult dosing.
Seizures, partial onset:
Children 3 to 4 years: Oral (excluding Gralise) Initial: 10 to 15 mg/kg/day in 3 divided doses; titrate to effective dose over ~3 days; increase dosage based on response and tolerability; usual dosage: 40 mg/kg/day in 3 divided doses; dosages of up to 50 mg/kg/day have been tolerated in clinical studies:
Children 5 to 11 years: Oral (excluding Gralise): Initial: 10 to 15 mg/kg/day in 3 divided doses; titrate to effective dose over ~3 days; increase dosage based on response and tolerability; usual dosage: 25 to 35 mg/kg/day in 3 divided doses; dosages of up to 50 mg/kg/day have been tolerated in clinical studies
Children ≥12 years: Refer to adult dosing.
Note: If gabapentin is discontinued or if another anticonvulsant is added to therapy, it should be done slowly over a minimum of 1 week
Dosing: Renal Impairment
Children ≥12 years and Adults:
All products, excluding Gralise:
CrCl ≥60 mL/minute: 300 to 1,200 mg 3 times daily
CrCl >30 to 59 mL/minute: 200 to 700 mg twice daily
CrCl >15 to 29 mL/minute: 200 to 700 mg once daily
CrCl 15 mL/minute: 100 to 300 mg once daily
CrCl <15 mL/minute: Reduce daily dose in proportion to creatinine clearance based on dose for creatinine clearance of 15 mL/minute (eg, reduce dose by one-half [range: 50 to 150 mg/day] for CrCl 7.5 mL/minute)
ESRD requiring hemodialysis: Dose based on CrCl plus a single supplemental dose of 125 to 350 mg (given after each 4 hours of hemodialysis)
Gralise only: Note: Follow initial dose titration schedule if treatment-naive.
CrCl ≥60 mL/minute: 1,800 mg once daily
CrCl >30 to 59 mL/minute: 600 to 1,800 mg once daily; dependent on tolerability and clinical response
CrCl <30 mL/minute: Use is not recommended.
ESRD requiring hemodialysis: Use is not recommended.
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer's labeling; however, gabapentin is not hepatically metabolized.
Note: Commercial oral solution is available (50 mg/mL)
A 100 mg/mL suspension may be made with tablets (immediate release) and either a 1:1 mixture of Ora-Sweet® (100 mL) and Ora-Plus® (100 mL) or 1:1 mixture of methylcellulose 1% (100 mL) and Simple Syrup N.F. (100 mL). Crush sixty-seven 300 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to almost 200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 200 mL. Label "shake well" and "refrigerate". Stable for 91 days refrigerated (preferred) or 56 days at room temperature.Nahata MC, Pai VB, and Hipple TF, Pediatric Drug Formulations, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.
Capsule, tablet (excluding Gralise), solution: May administer without regards to meals. Administer first dose on first day at bedtime to avoid somnolence and dizziness. Dosage must be adjusted for renal function; when given 3 times daily, the maximum time between doses should not exceed 12 hours.
Gralise: Take with evening meal. Swallow whole; do not chew, crush, or split.
Gralise should be taken with food.
Capsules and tablets: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Use scored 600 or 800 mg tablets that are broken in half within 28 days of breaking the tablet.
Oral solution: Store refrigerated at 2°C to 8°C (36°F to 46°F).
Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Monitor therapy
Antacids: May decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after antacid administration. Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used. Consider therapy modification
Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). Avoid combination
Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Consider therapy modification
Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants. Consider therapy modification
Cannabis: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Exceptions: Levocabastine (Nasal). Monitor therapy
Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended. Monitor therapy
Dronabinol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use. Consider therapy modification
Hydrocodone: CNS Depressants may enhance the CNS depressant effect of Hydrocodone. Management: Consider starting with a 20% to 30% lower hydrocodone dose when using together with any other CNS depressant. Dose reductions in the other CNS depressant may also be warranted. Consider therapy modification
HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Kava Kava: May enhance the adverse/toxic effect of CNS Depressants. Monitor therapy
Magnesium Salts: May enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after oral magnesium salts administration. Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used. Consider therapy modification
Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions. Monitor anticonvulsant concentrations and treatment response closely with concurrent use. Consider therapy modification
Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established. Consider therapy modification
Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine. Monitor therapy
Mianserin: May diminish the therapeutic effect of Anticonvulsants. Monitor therapy
Minocycline: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. Monitor therapy
Morphine (Systemic): Gabapentin may enhance the CNS depressant effect of Morphine (Systemic). Morphine (Systemic) may increase the serum concentration of Gabapentin. Monitor therapy
Nabilone: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Orlistat: May decrease the serum concentration of Anticonvulsants. Monitor therapy
Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Avoid combination
OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: When oxycodone is combined with another CNS depressant, a dose reduction of one or both agents should be considered. The extended release oxycodone starting dose should be reduced 50% to 67% when initiated in patients already receiving CNS depressants. Consider therapy modification
Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Avoid combination
Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination. Consider therapy modification
Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Monitor therapy
ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Monitor therapy
Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Monitor therapy
Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Monitor therapy
Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Monitor therapy
Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated. Consider therapy modification
Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Consider therapy modification
Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Start tapentadol at a dose of one-third to one-half of the normal dose if being initiated in a patient who is taking another drug with CNS depressant effects. Monitor closely for evidence of excessive CNS depression. Consider therapy modification
Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Avoid combination
Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Consider therapy modification
False positives have been reported with the Ames N-Multistix SG® dipstick test for urine protein
As reported for immediate release (IR) formulations in patients >12 years of age, unless otherwise noted in children (3-12 years) or with use of Gralise
Central nervous system: Dizziness (IR: 17% to 28%; children 3%; Gralise: 11%), drowsiness (IR: 19% to 21%; children 8%; Gralise: 5%), ataxia (1% to 13%), fatigue (11%; children 3%)
Infection: Viral infection (children 11%)
1% to 10%:
Cardiovascular: Peripheral edema (IR: 2% to 8%; Gralise: 4%), vasodilatation (1%)
Central nervous system: Hostility (children 5% to 8%), tremor (7%), emotional lability (children 4% to 6%), hyperkinesia (children 3% to 5%), headache (children and adolescents 3%), abnormality in thinking (2% to 3%; children 2%), abnormal gait (2%), amnesia (2%), depression (2%), nervousness (2%), pain (Gralise: 1% to 2%), hyperesthesia (1%), lethargy (Gralise: 1%), twitching (1%), vertigo (Gralise: 1%)
Dermatologic: Pruritus (1%), skin rash (1%)
Endocrine & metabolic: Weight gain (IR: Adults and children 2% to 3%; Gralise: 2%), hyperglycemia (1%)
Gastrointestinal: Diarrhea (IR: 6%), nausea and vomiting (3% to 4%; children 8%), xerostomia (IR: 2% to 5%; Gralise: 3%), constipation (IR: 1% to 4%; Gralise: 1%), abdominal pain (3%), dyspepsia (IR: 2%; Gralise: 1%), dry throat (2%), dental disease (2%), flatulence (2%), increased appetite (1%)
Genitourinary: Impotence (2%), urinary tract infection (Gralise: 2%)
Hematologic & oncologic: Decreased white blood cell count (1%), leukopenia (1%)
Infection: Infection (5%)
Neuromuscular & skeletal: Weakness (6%), back pain (IR: 2%; Gralise: 2%), dysarthria (2%), limb pain (Gralise: 2%), myalgia (2%), bone fracture (1%)
Ophthalmic: Nystagmus (8%), diplopia (1% to 6%), blurred vision (3% to 4%), conjunctivitis (1%)
Otic: Otitis media (1%)
Respiratory: Rhinitis (4%), bronchitis (children 3%), nasopharyngitis (Gralise: 3%), respiratory tract infection (children 3%), pharyngitis (1% to 3%), cough (2%)
Miscellaneous: Fever (children 10%)
Postmarketing and case reports (Limited to important or life-threatening): Acute renal failure, altered serum glucose, anaphylaxis, anemia, angina pectoris, angioedema, aphasia, aspiration pneumonia, blindness, blood coagulation disorder, bradycardia, brain disease, breast hypertrophy, cardiac arrhythmia (various), cardiac failure, cerebrovascular accident, CNS neoplasm, colitis, confusion, Cushingoid appearance, DRESS syndrome, drug abuse, drug dependence, erythema multiforme, facial paralysis, fecal incontinence, gastroenteritis, glaucoma, glycosuria, hearing loss, heart block, hematemesis, hematuria, hemiplegia, hemorrhage, hepatitis, hepatomegaly, herpes zoster, hyperlipidemia, hypertension, hyperthyroidism, hyperventilation, hyponatremia, hypotension, hypothyroidism, hypoventilation, increased creatine phosphokinase, increased liver enzymes, increased serum creatinine, jaundice, joint swelling, leukocytosis, lymphadenopathy, lymphocytosis, memory impairment, meningism, migraine, movement disorder, myocardial infarction, myoclonus (local), nephrolithiasis, nephrosis, nerve palsy, non-Hodgkin's lymphoma, ovarian failure, pancreatitis, peptic ulcer, pericardial effusion, pericardial rub, pericarditis, peripheral vascular disease, pneumonia, psychosis, pulmonary thromboembolism, purpura, retinopathy, rhabdomyolysis, seasonal allergy, skin necrosis, status epilepticus, Stevens-Johnson syndrome, subdural hematoma, suicidal ideation, suicidal tendencies, syncope, tachycardia, thrombocytopenia, thrombophlebitis, tumor growth, withdrawal syndrome
Concerns related to adverse effects:
• Anaphylaxis/angioedema: May occur after the first dose or at any time during treatment. Discontinue therapy and seek immediate medical care if signs or symptoms of anaphylaxis or angioedema occur.
• CNS depression: May cause CNS depression including somnolence and dizziness, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).
• Multiorgan hypersensitivity: Potentially serious, sometimes fatal multiorgan hypersensitivity (also known as drug reaction with eosinophilia and systemic symptoms [DRESS]) has been reported with some antiepileptic drugs, including gabapentin. Monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, cardiac, and/or hematologic systems; fever, rash, and eosinophilia may also be present. Discontinue immediately if suspected.
• Neuropsychiatric effects: Use in pediatric patients with epilepsy has been associated with the occurrence of CNS adverse effects of mild to moderate intensity. The most significant include emotional lability, hostility (eg, aggressive behaviors), changes in behavior and thinking (eg, concentration problems and changes in school performance), and hyperkinesia (primarily restlessness and hyperactivity).
• Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials ≤24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.
• Renal impairment: Use with caution in patients with severe renal impairment; dose adjustment required.
• Seizure disorder: The safety and efficacy of Gralise has not been studied in patients with epilepsy.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
Dosage form specific issues:
• Product interchangeability: Gabapentin immediate release and Gralise products are not interchangeable with each other or with gabapentin enacarbil (Horizant) due to differences in formulations, indications, and pharmacokinetics.
• Tumorigenic potential: Male rat studies demonstrated an association with pancreatic adenocarcinoma (clinical implication in humans is unknown).
• Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. Gralise should be withdrawn over ≥1 week.
Monitor serum levels of concomitant anticonvulsant therapy; suicidality (eg, suicidal thoughts, depression, behavioral changes)
Pregnancy Risk Factor
Adverse events have been observed in animal reproduction studies. Gabapentin crosses the placenta. In a small study (n=6), the umbilical/maternal plasma concentration ratio was ~1.74. Neonatal concentrations declined quickly after delivery and at 24 hours of life were ~27% of the cord blood concentrations at birth (gabapentin neonatal half-life ~14 hours) (Ohman 2005). Outcome data following maternal use of gabapentin during pregnancy is limited (Holmes 2012).
Patients exposed to gabapentin during pregnancy are encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience dizziness, fatigue, nausea, diarrhea, or xerostomia. Have patient report immediately to prescriber signs of hepatic impairment, signs of renal impairment, memory impairment, vision changes, illogical thinking, tremors, dyspnea, excessive weight gain, edema of extremities, severe asthenia, involuntary eye movements, fasciculations, ecchymosis, hemorrhaging, chills, pharyngitis, myalgia, change in balance, difficulty speaking, difficulty focusing, suicidal ideation, depression, anxiety, akathisia, irritability, panic attacks, or mood changes (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.
More about gabapentin
- Gabapentin (AHFS Monograph)
- Gabapentin (FDA)
- Gabapentin Capsules (FDA)
- Gabapentin Oral Solution (FDA)
- Gabapentin Tablets (FDA)